Current Strategy for Implementing Advanced Tech to Address Multidrug- Resistant Bacteria
Rajeshwar V. and Vasudha B. and Somasundaram I. and Sridevi Ganesan and Shanmugam Vippamakula and Vasanth Kumar Mohan6 (2025) Current Strategy for Implementing Advanced Tech to Address Multidrug- Resistant Bacteria. Current Strategy for Implementing Advanced Tech to Address Multidrug- Resistant Bacteria: e221135253. ISSN 2211-3533
Current Strategy for Implementing Advanced Tech to Address Multidrug-.pdf - Published Version
Download (772kB)
Abstract
Introduction: This review explores emerging technological strategies aimed at combating
Multidrug-Resistant Bacteria (MDRB), including MRSA, CRE, and VRE. These pathogens
pose a critical public health threat due to rising resistance to conventional antibiotics. The
study synthesizes findings on advanced approaches like nanotechnology, host-directed therapies,
novel antimicrobials, combination regimens, and phytochemicals.
Methods: A comprehensive literature review was performed using databases such as PubMed,
Scopus, Web of Science, and Google Scholar, with keywords including “nanoparticles,” “hostdirected
therapy,” and “phytochemicals.” Inclusion criteria prioritized peer-reviewed studies on
antimicrobial interventions for MDRB. Data were grouped thematically and analyzed narratively
to identify effective technologies and existing research gaps.
Results: Nanoparticles (e.g., AgNPs, ZnO NPs) showed antibacterial effects via membrane disruption
and reactive oxygen species generation. Host-directed therapies, like cytokine modulators
and immune checkpoint inhibitors, improved bacterial clearance. New antibiotics such as
Cefiderocol and Eravacycline effectively targeted resistant Gram-negative strains. Combination
therapies improved antibiotic efficacy, especially against biofilm-forming bacteria. Phytochemicals
such as gingerol enhanced antibiotic activity and disrupted resistance mechanisms.
Discussion: These technologies offer promising alternatives to failing antibiotics, especially
against pathogens with complex resistance mechanisms. However, limitations include toxicity
concerns (nanoparticles), immunological variability (host therapies), lack of clinical validation,
and cost barriers. Integration into clinical practice remains limited by regulatory and logistical
challenges.
Conclusion: Advanced therapeutic strategies hold strong potential for addressing MDRB. However,
successful clinical translation requires further research, global cooperation, and investment
in regulatory infrastructure.
| Item Type: | Article |
|---|---|
| Domains: | Allied Health Sciences |
| Depositing User: | Mr IR Admin |
| Date Deposited: | 12 May 2026 09:31 |
| Last Modified: | 12 May 2026 09:31 |
| URI: | https://ir.vistas.ac.in/id/eprint/18065 |
